Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

boceprevir (Discontinued)Brand and Other Names:Victrelis

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 200mg
more...

Chronic Hepatitis C

Discontinued; sale and distribution of boceprevir will be discontinued in the United States by December 2015

Indicated for treatment of chronic hepatitis C (CHC) genotype 1 infection in combination with peginterferon alfa and ribavirin

Indication is specifically for adults with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy

Initiate therapy with peginterferon alfa and ribavirin for 4 weeks, THEN

Add boceprevir 800 mg PO q8hr (ie, q7-9hr) with food

Treatment Duration

Duration of treatment depends on HCV-RNA levels at treatment weeks 8, 12, and 24

HCV-RNA levels at 8 weeks

  • Previously untreated and HCV-RNA levels undetectable: Complete 3-medication regimen at week 28
  • Previously untreated and HCV-RNA levels detectable: Continue 3 medication regimen through week 36, then continue peginterferon alfa and ribavirin through week 48
  • Partial responders or relapsed and HCV-RNA levels undetectable: Complete 3-medication regimen at week 36
  • Partial responders or relapsed and HCV-RNA levels detectable: Continue 3 medication regimen through week 36, then continue peginterferon alfa and ribavirin through week 48

HCV-RNA levels at 12 weeks

  • Response-guided therapy was not studied in individuals who had less than a 2-log10 HCV-RNA decline by treatment week 12 during prior therapy with peginterferon alfa and ribavirin
  • If considered for treatment, these patients should receive peginterferon alfa and ribavirin x4 weeks followed by boceprevir x44 weeks in combination with peginterferon alfa and ribavirin
  • In addition, consideration should be given to treating previously untreated patients who are poorly interferon responsive (as determined at TW 4) with 4 weeks peginterferon alfa and ribavirin followed by boceprevir x44 weeks in combination with peginterferon alfa and ribavirin in order to maximize rates of a sustained virologic response

HCV-RNA levels at 24 weeks

  • If HCV-RNA levels are undetectable at treatment week 24, continue with treatment regimen identified at week 8

Treatment futility

  • Discontinuation of therapy is recommended in all patients with any of the following circumstances:
  • If HCV-RNA levels ≥1000 IU/mL at week 8, discontinue 3-medication regimen, OR
  • If HCV-RNA levels ≥100 IU/mL at week 12, discontinue 3-medication regimen, OR
  • If confirmed, detectable HCV-RNA levels at week 24, discontinue 3-medication regimen

Compensated cirrhosis

  • Peginterferon alfa and ribavirin x 4 weeks followed by boceprevir x44 weeks in combination with peginterferon alfa and ribavirin

Renal or Hepatic Impairment

No dose adjustment for boceprevir is required

See peginterferon alfa and ribavirin monographs for recommended dose adjustments

Administration

Must be administered in combination with peginterferon alfa and ribavirin

Administer with a meal or light snack

<18 years: Safety and efficacy not established

Next

Interactions

Interaction Checker

boceprevir and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Fatigue (55-58%)

            Anemia (45-50%)

            Nausea (43-46%)

            Headache (>35%)

            Dysgeusia (35-44%)

            Insomnia (30-34%)

            Chills (33-34%)

            Alopecia (22-27%)

            Diarrhea (25%)

            Anorexia (25%)

            Neutropenia (14-25%)

            Arthralgia (19-23%)

            Irritability (21-22%)

            Dry skin (18-22%)

            Asthenia (15-21%)

            Vomiting (15-20%)

            Dizziness (16-19%)

            Rash (16-17%)

            Xerostomia (11-15%)

            Exertional dyspnea (8-11%)

            Postmarketing Reports

            Blood and lymphatic system disorders: Agranulocytosis, pancytopenia, thrombocytopenia

            Gastrointestinal disorders: Mouth ulceration, stomatitis

            Infections and Infestations: Pneumonia, sepsis

            Skin and subcutaneous tissue disorders: Angioedema, urticaria; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma

            Previous
            Next

            Warnings

            Contraindications

            Coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events

            Potent CYP3A4/5 inducers where significantly reduced boceprevir plasma concentrations may be associated with reduced efficacy

            Hypersensitivity

            Also consider contraindications to peginterferon alfa and ribavirin

            Because ribavirin may cause birth defects and fetal death, boceprevir in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant

            Cautions

            Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients; patients must have a negative pregnancy test prior to therapy; use 2 or more forms of contraception, 1 of these forms of contraception can be a combined oral contraceptive product containing at least 1 mg of norethindrone (lower doses of norethindrone and other forms of hormonal contraception have not been studied or are contraindicated)

            Perform monthly pregnancy tests in sexually active women

            Serious acute hypersensitivity reactions (eg, urticaria, angioedema) reported

            Anemia: Addition of boceprevir to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations compared with peginterferon alfa and ribavirin alone

            Neutropenia: Addition of boceprevir to peginterferon alfa and ribavirin may result in worsening of neutropenia associated with peginterferon alfa and ribavirin therapy alone

            Pancytopenia reported; obtain CBC pretreatment and at treatment weeks 2, 4, 8, and 12, and periodically thereafter as clinically appropriate

            Safety and efficacy not established with decompensated cirrhosis, organ transplant, or coinfection with HIV or HBV

            Potential inhibitor of p-glycoprotein (P-gp) based on in vitro studies; the potential for a drug interaction with sensitive substrates of p-glycoprotein (eg, digoxin) has not been evaluated in a clinical trial

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: X

            Boceprevir is coadministered with ribavirin; significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; and therefore ribavirin is contraindicated in women who are pregnant and in the male partners of women who are pregnant

            Lactation: Unknown whether distributed in breast milk; because of the potential for adverse reaction, breastfeeding is not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits HCV NS3/4A protease needed for proteolytic cleavage of the HCV encoded polyprotein into mature forms, which in turn inhibits replication of the hepatitis C virus

            Absorption

            Peak plasma time: 2 hr peak

            Plasma concentration: 1723 ng/mL

            AUC: 5408 ng•hr/mL Should be administered with food; food enhanced the exposure of boceprevir by up to 65%

            Distribution

            Protein bound: 75%

            Vd: 772 L (at steady state)

            Metabolism

            Primarily undergoes metabolism through the aldoketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV; also undergoes, to a lesser extent, oxidative metabolism mediated by CYP3A4/5

            Metabolized by aldoketoreductase (AKR), CYP3A4/5 (partial)

            Enzymes inhibited: Strong CYP3A4/5 inhibitor

            Elimination

            Half-life: 3.4 hr

            Total body clearance: 161 L/hr

            Excretion: feces (79%), urine (9%)

            Pharmacogenomics

            A genetic variant near the gene encoding interferon-lambda-3 (IL28B rs12979860, a C to T change) is a strong predictor of response to peginterferon and ribavirin

            Sustained virologic response rates tended to be lower with the C/T and T/T genotypes compared to those with the C/C genotype, particularly among previously untreated subjects receiving 48 weeks of peginterferon and ribavirin

            Previous
            Next

            Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.